入会
发表于 2025-3-25 04:28:42
Cholangiocarcinoma,modal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric
Gullible
发表于 2025-3-25 07:45:25
Recurrent Non-hepatic and De Novo Malignancies After Liver Transplantation,rson-years calculated by adding survival of each patient) are compared with epidemiological data for each cancer type. This method provides the precise incidence of cancer post-LTx compared to general population. Rates of malignancy increase in proportion to age at transplant and length of follow-up
称赞
发表于 2025-3-25 13:18:16
http://reply.papertrans.cn/29/2813/281259/281259_23.png
commodity
发表于 2025-3-25 17:31:15
http://reply.papertrans.cn/29/2813/281259/281259_24.png
不适当
发表于 2025-3-25 22:13:09
Ivica Milevski,Ekaterina Ivanovaotentially reverses the consequences and complications of the initial abnormalities depending on the severity of the complications, reversibility, and time interval between the diagnosis of the problem and replacement of the liver.
横条
发表于 2025-3-26 00:09:16
http://reply.papertrans.cn/29/2813/281259/281259_26.png
阐释
发表于 2025-3-26 04:47:32
http://reply.papertrans.cn/29/2813/281259/281259_27.png
Cerumen
发表于 2025-3-26 11:05:50
vered.As there is a high incidence of disease recurrence after liver transplantation, this volume is designed around the need for a reference text dealing exclusively with this problem. The book places special emphasis on pre- and post-transplant predictors of recurrence, severity assessment, prophy
forager
发表于 2025-3-26 14:10:09
http://reply.papertrans.cn/29/2813/281259/281259_29.png
北京人起源
发表于 2025-3-26 18:50:32
Ivica Milevski,Ekaterina Ivanovaion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.